- Home
- IGMS vs ELTK Comparison
IGMS vs ELTK Comparison
Compare IGMS & ELTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- ELTK
- Stock Information
- Founded
- IGMS 1993
- ELTK 1970
- Country
- IGMS United States
- ELTK Israel
- Employees
- IGMS N/A
- ELTK N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- ELTK Electrical Products
- Sector
- IGMS Health Care
- ELTK Technology
- Exchange
- IGMS Nasdaq
- ELTK Nasdaq
- Market Cap
- IGMS 82.1M
- ELTK 69.5M
- IPO Year
- IGMS 2019
- ELTK 1997
- Fundamental
- Price
- IGMS $1.36
- ELTK N/A
- Analyst Decision
- IGMS Hold
- ELTK
- Analyst Count
- IGMS 8
- ELTK 0
- Target Price
- IGMS $6.00
- ELTK N/A
- AVG Volume (30 Days)
- IGMS 1.1M
- ELTK 37.8K
- Earning Date
- IGMS 08-13-2025
- ELTK 08-14-2025
- Dividend Yield
- IGMS N/A
- ELTK 1.85%
- EPS Growth
- IGMS N/A
- ELTK N/A
- EPS
- IGMS N/A
- ELTK 0.51
- Revenue
- IGMS $2,681,000.00
- ELTK $47,500,000.00
- Revenue This Year
- IGMS $134.30
- ELTK $18.60
- Revenue Next Year
- IGMS $22.37
- ELTK $9.04
- P/E Ratio
- IGMS N/A
- ELTK $19.98
- Revenue Growth
- IGMS 27.36
- ELTK 1.05
- 52 Week Low
- IGMS $0.92
- ELTK $7.65
- 52 Week High
- IGMS $22.50
- ELTK $12.19
- Technical
- Relative Strength Index (RSI)
- IGMS 59.58
- ELTK 50.95
- Support Level
- IGMS $1.12
- ELTK $10.17
- Resistance Level
- IGMS $1.39
- ELTK $11.69
- Average True Range (ATR)
- IGMS 0.08
- ELTK 0.73
- MACD
- IGMS 0.01
- ELTK -0.02
- Stochastic Oscillator
- IGMS 83.87
- ELTK 49.47
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About ELTK Eltek Ltd.
Eltek Ltd is engaged in the technology business sector that manufactures and supplies technologically new custom-made circuitry solutions. It manufactures, markets, and sells custom-made printed circuit boards (PCBs), including high-density interconnect, flex-rigid and multi-layered boards. The Company markets its products mainly to the medical technology, defense and aerospace, industrial, telecom, and networking equipment industries. Its geographic areas are Israel, North America, the Netherlands, India, and Others. It generates the majority of its revenue from Israel.